DAWN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DAWN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Day One Biopharmaceuticals's Forward PE Ratio for today is 0.00.
Day One Biopharmaceuticals's PE Ratio without NRI for today is 0.00.
Day One Biopharmaceuticals's PE Ratio for today is 0.00.
The historical data trend for Day One Biopharmaceuticals's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Day One Biopharmaceuticals Annual Data | |
Trend | |
Forward PE Ratio |
Day One Biopharmaceuticals Quarterly Data |
Forward PE Ratio |
For the Biotechnology subindustry, Day One Biopharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Day One Biopharmaceuticals's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Day One Biopharmaceuticals (NAS:DAWN) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Thank you for viewing the detailed overview of Day One Biopharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
York Charles N Ii | officer: COO, CFO and Secretary | 901 S. MOPAC EXPRESSWAY, BARTON OAKS PLAZA ONE, SUITE 250, AUSTIN TX 78746 |
Samuel C. Blackman | officer: Chief Medical Officer | 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080 |
Jeremy Bender | director, officer: Chief Executive Officer | 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080 |
Ai Day 1 Llc | 10 percent owner | 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019 |
Julie Papanek Grant | director | 2765 SAND HILL ROAD, MENLO PARK CA 94025 |
Canaan Xi L.p. | 10 percent owner | 2765 SAND HILL RD, MENLO PARK CA 94025 |
Garry A Nicholson | director | C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
Atlas Venture Opportunity Fund Ii, L.p. | 10 percent owner | 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
Michael Gladstone | director | 395 OYSTER POINT BLVD, SUITE 217, SOUTH SAN FRANCISCO CA 94080 |
Atlas Venture Fund Xi, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668 |
Takeda Pharmaceuticals U.s.a., Inc. | 10 percent owner | ONE TAKEDA PARKWAY, DEERFIELD IL 60015 |
Takeda Ventures, Inc. | 10 percent owner | 9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121 |
J. Scott Garland | director | 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
John A. Josey | director | C/O PELOTON THERAPEUTICS, INC., 2330 INWOOD ROAD, SUITE 226, DALLAS TX 75235 |
From GuruFocus
By Value_Insider Value_Insider • 10-17-2022
By GlobeNewswire GlobeNewswire • 05-26-2023
By Value_Insider Value_Insider • 12-20-2022
By GuruFocus Research • 11-06-2023
By GlobeNewswire GlobeNewswire • 06-04-2023
By sperokesalga sperokesalga • 06-06-2023
By Marketwired • 08-07-2023
By Value_Insider Value_Insider • 11-11-2022
By sperokesalga sperokesalga • 06-04-2023
By sperokesalga sperokesalga • 05-30-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.